Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis

American Journal of Pathology

Volumn 173, Issue 2, 2008, Pages 411-422

  Elyaman, Wassim ^a   Kivisäkk, Pia ^a   Reddy, Jay ^a   Chitnis, Tanuja ^a   Raddassi, Khadir ^a   Imitola, Jaime ^a   Bradshaw, Elizabeth ^a   Kuchroo, Vijay K ^a   Yagita, Hideo ^b   Sayegh, Mohamed H ^a   Khoury, Samia J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BIOLOGICAL MARKER; CD134 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 17; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; IMMUNOMODULATION; IN VIVO CULTURE; MEMORY T LYMPHOCYTE; MOUSE; NERVE CELL LESION; NERVE FIBER; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

EID: 48749103314     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.080142     Document Type: Article

References (59)

1. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175
2. Imitola J, Chitnis T, Khoury SJ: Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol 2006, 63:25-33
3. Selmaj K, Brosnan CF, Raine CS: Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis, Proc Natl Acad Sci USA 1991, 88:6452-6456
4. Weiner HL: Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004, 61:1613-1615
5. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA: Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994, 179:973-984
6. Allegretta M, Nicklas JA, Sriram S, Albertini RJ: T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990, 247:718-721
7. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK: Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998, 101:725-730
8. Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R: CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest 2001, 108:1185-1194
9. Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA: Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 1998, 160:1532-1538
10. Lakkis FG, Sayegh MH: Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003, 14:2402-2410
11. Dutton RW, Bradley LM, Swain SL: T cell memory. Annu Rev Immunol 1998, 16:201-223
12. Kaech SM, Wherry EJ, Ahmed R: Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2:251-262
13. Masopust D, Vezys V, Marzo AL, Lefrancois L: Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001, 291:2413-2417
14. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK: Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001, 410:101-105
15. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712
16. Chitnis T, Khoury SJ: Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis, J Allergy Clin Immunol 2003, 112:837-849 quiz 850
17. Keir ME, Sharpe AH: The B7/CD28 costimulatory family in autoimmunity. Immunol Rev 2005, 204:128-143
18. Khoury SJ, Sayegh MH: The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004, 20:529-538
19. Croft M, Bradley LM, Swain SL: Naïve versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994, 152:2675-2685
20. London CA, Lodge MP, Abbas AK: Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol 2000, 164:265-272
21. Ndejembi MP, Teijaro JR, Patke DS, Bingaman AW, Chandok MR, Azimzadeh A, Nadler SG, Farber DL: Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006, 177:7698-7706
22. Borowski AB, Boesteanu AC, Mueller YM, Carafides C, Topham DJ, Altman JD, Jennings SR, Katsikis PD: Memory CD8+ T cells require CD28 costimulation. J Immunol 2007, 179:6494-6503
23. Chitnis T, Najafian N, Benou C, Salama AD, Grusby MJ, Sayegh MH, Khoury SJ: Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001, 108:739-747
24. Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, Coccia MA, Kohno T, Tafuri-Bladt A, Brankow D, Campbell P, Chang D, Chiu L, Dai T, Duncan G, Elliott GS, Hui A, McCabe SM, Scully S, Shahinian A, Shaklee CL, Van G, Mak TW, Senaldi G: T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999, 402:827-832
25. Akiba H, Atsuta M, Yagita H, Okumura K: Identification of rat OX40 ligand by molecular cloning. Biochem Biophys Res Commun 1998, 251:131-136
26. Judge AD, Zhang X, Fujii H, Surh CD, Sprent J: Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med 2002, 196:935-946
27. Freitas AA, Rocha B: Peripheral T cell survival. Curr Opin Immunol 1999, 11:152-156
28. Goldrath AW, Bevan MJ: Selecting and maintaining a diverse T-cell repertoire. Nature 1999, 402:255-262
29. Werner P, Pitt D, Raine CS: Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001, 50:169-180
30. Jessen KR, Mirsky R: Glial cells in the enteric nervous system contain glial fibrillary acidic protein. Nature 1980, 286:736-737
31. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, Hancock WW: CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995, 155:4521-4524
32. Miller SD, Vanderlugt CL, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, Bluestone JA: Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995, 3:739-745
33. Koehn B, Gangappa S, Miller JD, Ahmed R, Larsen CP: Patients, pathogens, and protective immunity: the relevance of virus-induced alloreactivity in transplantation. J Immunol 2006, 176:2691-2696
34. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrancois L: Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol 2005, 6:793-799
35. Vincenz C, Dixit VM: Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. J Biol Chem 1997, 272:6578-6583
36. Guarda G, Hons M, Soriano SF, Huang AY, Polley R, Martin-Fontecha A, Stein JV, Germain RN, Lanzavecchia A, Sallusto F: L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol 2007, 8:743-752
37. Callahan MK, Williams KA, Kivisakk P, Pearce D, Stins MF, Ransohoff RM: CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol 2004, 153:150-157
38. Akashi S, Sho M, Kashizuka H, Hamada K, Ikeda N, Kuzumoto Y, Tsurui Y, Nomi T, Mizuno T, Kanehiro H, Hisanaga M, Ko S, Nakajima Y: A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 2005, 80:378-384
39. Song K, Rabin RL, Hill BJ, De Rosa SC, Perfetto SP, Zhang HH, Foley JF, Reiner JS, Liu J, Mattapallil JJ, Douek DC, Roederer M, Farber JM: Characterization of subsets of CD4+ memory T cells reveals early branched pathways of T cell differentiation in humans. Proc Natl Acad Sci USA 2005, 102:7916-7921
40. Rabin RL, Alston MA, Sircus JC, Knollmann-Ritschel B, Moratz C, Ngo D, Farber JM: CXCR3 is induced early on the pathway of CD4+ T cell differentiation and bridges central and peripheral functions. J Immunol 2003, 171:2812-2824
41. -/- mice with experimental autoimmune encephalomyelitis. J Immunol 2006, 176:4399-4409
42. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352
43. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y: IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003, 100:5986-5990
44. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132
45. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141
46. Flynn K, Mullbacher A: Memory alloreactive cytotoxic T cells do not require costimulation for activation in vitro. Immunol Cell Biol 1996, 74:413-420
47. Perrin PJ, Lovett-Racke A, Phillips SM, Racke MK: Differential requirements of naïve and memory T cells for CD28 costimulation in autoimmune pathogenesis. Histol Histopathol 1999, 14:1269-1276
48. Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, Trotter JL, Karr RW: Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest 1995, 95:2783-2789
49. Khoury SJ, Gallon L, Verburg RR, Chandraker A, Peach R, Linsley PS, Turka LA, Hancock WW, Sayegh MH: Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1996, 157:3700-3705
50. Perrin PJ, Scott D, Quigley L, Albert PS, Feder O, Gray GS, Abe R, June CH, Racke MK: Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol 1995, 154:1481-1490
51. Demirci G, Amanullah F, Kewalaramani R, Yagita H, Strom TB, Sayegh MH, Li XC: Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004, 172:1691-1698
52. Vu MD, Amanullah F, Li Y, Demirci G, Sayegh MH, Li XC: Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection. J Immunol 2004, 173:214-221
53. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA: Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004, 10:87-92
54. Rottman JB, Smith T, Tonra JR, Ganley K, Bloom T, Silva R, Pierce B, Gutierrez-Ramos JC, Ozkaynak E, Coyle AJ: The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001, 2:605-611
55. Gramaglia I, Weinberg AD, Lemon M, Croft M: Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998, 161:6510-6517
56. Lathrop SK, Huddleston CA, Dullforce PA, Montfort MJ, Weinberg AD, Parker DC: A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J Immunol 2004, 172:6735-6743
57. Dawicki W, Bertram EM, Sharpe AH, Watts TH: 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 2004, 173:5944-5951
58. Evan AP, Bledsoe SB, Connors BA, Deng L, Liang L, Shao C, Fineberg NS, Grynpas MD, Stambrook PJ, Youzhi S, Sahota A, Tischfield JA: Sequential analysis of kidney stone formation in the Aprt knockout mouse. Kidney Int 2001, 60:910-923
59. Vu MD, Clarkson MR, Yagita H, Turka LA, Sayegh MH, Li XC: Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol 2006, 176:1394-1401